| Literature DB >> 30733850 |
Heba M A Abdelrazek1, Manal M A Mahmoud2, Hend M Tag3,4, Sahar M Greish5,6, Dalia A Eltamany7, Mohammed T A Soliman8.
Abstract
Hormone replacement therapy (HRT) can alleviate estrogen deficiency symptoms especially during menopause. The present study aimed at investigating the effect of soy isoflavones as HRT on immunological and bone health-related parameters with a special focus on the interactions between immunological status and metabolism. Thirty healthy cyclic female Wistar rats were used in this experiment. Ten females were sham-operated, and 20 females were subjected to ovariectomy. Overiectomized (OVX) female rats were randomly divided into 2 groups: the control group (G1, OVX/casein) was fed a casein-based diet, and the second group (G2, OVX/soy) was fed a high soy isoflavone diet. Both groups were compared to a sham-operated group (G3, sham/casein). Treatments continued for 7 weeks. Feed intake, weight gain, and lymphoid organ relative weights were recorded. Some metabolic, immunological, and bone health-related parameters were measured. Moreover, nitric oxide (NO), malondialdehyde (MDA), and total antioxidant capacity (TAC) were determined. Bone histopathology and immunohistochemistry to estrogen receptor alpha (ERα) were done. Feeding soy to OVX females reduced feed intake, weight gain, relative lymphoid organ weight, and T-lymphocytes transformation. Soy isoflavone administration normalized nearly all metabolic and immunological parameters to a level comparable to the sham group via oxidative stress amelioration and bone ERα promotion. Soy isoflavones seemed to be good HRT in estrogen deprivation which modulated the appetite, weight gain, lipid profile, proinflammation, and bone turnover.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30733850 PMCID: PMC6348823 DOI: 10.1155/2019/5713606
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Diet composition.
| Ingredients | Control (%) | High isoflavones (%) |
|---|---|---|
| Yellow corn | 40.59 | 35.04 |
| Corn gluten | 15.00 | — |
| Soybean∗ | — | 26.41 |
| Casein | 5.00 | 5. 00 |
| Sucrose | 22.43 | 22.32 |
| Starch | 7.63 | 4.16 |
| Cellulose | 1.30 | — |
| Corn oil | 5.00 | — |
| Soybean oil | — | 5.00 |
| Methionine | 0.30 | 0.43 |
| Lysine | 0.26 | — |
| Tryptophan | 0.39 | — |
| Ground limestone | 0.58 | 0.70 |
| Dicalcium phosphate | 1.09 | 0.57 |
| Common salt | 0.13 | 0.13 |
| Premix∗∗ | 0.30 | 0.30 |
| Total | 100.00 | 100.00 |
|
| ||
| CP %∗∗∗ | 17.11 | 17.11 |
| ME (kcal/kg) | 3708.26 | 3703.05 |
| C/P ratio | 216.70 | 216.50 |
| Ca | 0.50 | 0.50 |
| P | 0.30 | 0.30 |
|
| ||
| Genistein ( | 0 | 1500 |
| Daidzein | 0 | 800 |
∗Soybean was autoclaved at 110°C for 30 minutes according to Westfall and Hauge [121] to inactivate the trypsin inhibitor, tannins, saponins, phytate, protease inhibitors, lectins, and goitrogens. ∗∗Each 3 kg contains the following vitamins and minerals: vit. A 12 mIU, vit. D3 2 mIU, vit. E 1000 mg, vit. k3 1000 mg, vit. B1 1000 mg, vit. B2 5000 mg, vit. B6 1500 mg, vit. B12 10 mg, biotin 50 mg, pantothenic acid 10000 mg, nicotinic acid 30000 mg, folic acid 1000 mg, manganese 60000 mg, zinc 50000 mg, iron 30000 mg, copper 4000 mg, iodine 300 mg, selenium 100 mg, cobalt 100 mg, and carrier (CaCO3) to 3 kg (Golden premix- Selim Pharm Elasher, Egypt.). ∗∗∗Analyzed according to Helrick [122].
Effect of soy isoflavones on feed intake (g/day/female), cumulative feed intake (g/female), weight gain (g/week), cumulative weight gain (g), and relative thymus and spleen weight (g%) among experimental groups.
| Parameters | G1 (OVX/casein) | G2 (OVX/soy) | G3 (sham/casein) | |
|---|---|---|---|---|
| Feed intake (g/day/female) | 1st week | 19.34 ± 1.11a | 17.20 ± 1.17a | 12.57 ± 0.68b |
| 2nd week | 18.75 ± 1.20a | 12.92 ± 0.86b | 11.65 ± 1.15b | |
| 3rd week | 17.40 ± 0.67a | 14.63 ± 0.56ab | 12.87 ± 1.5 1b | |
| 4th week | 16.42 ± 0.84a | 16.22 ± 1.03a | 11.77 ± 1.33b | |
| 5th week | 21.93 ± 2.77a | 18.51 ± 0.80ab | 13.21 ± 1.39b | |
| 6th week | 21.97 ± 3.44a | 18.37 ± 0.95ab | 13.80 ± 1.42b | |
| 7th week | 21.33 ± 1.36a | 16.68 ± 3.14a | 9.75 ± 0.57b | |
| Cumulative feed intake (g/female) | 956.22 ± 6.15a | 801.47 ± 5.41b | 599.48 ± 11.55c | |
|
| ||||
| Weight gain (g/week) | 2nd week | 19.70 ± 1.08a | 11.73 ± 1.91b | 9.47 ± 1.28b |
| 3rd week | 10.45 ± 1.58a | 10.65 ± 0.88a | 8.90 ± 1.10a | |
| 4th week | 12.19 ± 1.11a | 8.02 ± 0.80b | 5.37 ± 0.98b | |
| 5th week | 7.08 ± 1.12a | 6.73 ± 0.63a | 5.73 ± 0.37a | |
| 6th week | 6.32 ± 0.81a | 3.62 ± 0.40b | 2.97 ± 0.49b | |
| 7th week | 5.33 ± 0.96a | 1.05 ± 0.52b | 1.07 ± 0.47b | |
| Cumulative weight gain (g) | 44.12 ± 5.13a | 31.60 ± 5.01b | 23.45 ± 2.39b | |
|
| ||||
| Relative weight (g%) | Thymus | 0.35 ± 0.04a | 0.16 ± 0.02b | 0.32 ± 0.05a |
| Spleen | 0.58 ± 0.04a | 0.50 ± 0.09a | 0.45 ± 0.06a | |
a-cMeans in the same row with different superscripts are significantly different (p < 0.05); values are presented as means ± SEM.
Effect of soy isoflavones on serum lipid profile, ghrelin, calcitonin, ionized calcium, inorganic phosphorus, and alkaline phosphatase (ALP) among experimental groups.
| Parameters | G1 (OVX/casein) | G2 (OVX/soy) | G3 (sham/soy) |
|---|---|---|---|
| HDL-C (mg/dL) | 10.19 ± 0.41a | 12.58 ± 0.44b | 14.01 ± 0.20b |
| LDL-C (mg/dL) | 65.72 ± 1.96a | 55.08 ± 0.94b | 51.31 ± 4.72b |
| TG (mg/dL) | 109.80 ± 4.85a | 83.65 ± 8.49b | 83.15 ± 2.21b |
| TC (mg/dL) | 66.85 ± 2.41a | 58.32 ± 1.27b | 55.89 ± 2.87b |
| Ghrelin (pg/mL) | 545.80 ± 3.49a | 370.80 ± 6.55b | 369.50 ± 13.87b |
| Calcitonin (pg/mL) | 172.46 ± 5.98b | 249.90 ± 4.19a | 252.83 ± 2.50a |
| Resistin (ng/mL) | 0.87 ± 0.05a | 0.59 ± 0.04b | 0.61 ± 0.04b |
| Ionized Ca+2 (mg/dL) | 6.77 ± 0.35a | 5.77 ± 0.19b | 5.19 ± 0.30b |
| Phosphorus (mg/dL) | 6.04 ± 0.12a | 5.10 ± 0.33b | 4.98 ± 0.37b |
| ALP (IU/L) | 126.00 ± 5.12b | 190.80 ± 12.88a | 179.3 ± 3.57a |
a-bMeans in the same row with different superscripts are significantly different (p < 0.05); values are presented as means ± SEM.
Effect of soy isoflavones on lymphocyte transformation test (LTT), nitric oxide (NO), total antioxidant capacity (TAC), malondialdehyde (MDA), and inflammatory mediators among experimental groups.
| Parameters | G1 (OVX/casein) | G2 (OVX/soy) | G3 (sham/soy) |
|---|---|---|---|
| LTT | 0.65 ± 0.06a | 0.27 ± 0.04b | 0.51 ± 0.06a |
| NO ( | 29.41 ± 0.85a | 21.29 ± 0.91b | 21.84 ± 0.66b |
| TAC (mM/L) | 0.34 ± 0.12a | 0.82 ± 0.08b | 0.72 ± 0.04b |
| MDA (nM/L) | 1.97 ± 0.13a | 1.61 ± 0.07b | 1.53 ± 0.09b |
| TNF-alpha (pg/mL) | 8.99 ± 0.30a | 5.73 ± 0.56b | 5.25 ± 0.46b |
| IL-2 (pg/mL) | 5.74 ± 0.54a | 3.54 ± 0.27b | 3.39 ± 0.39b |
| COX-2 (ng/L) | 9.75 ± 0.42a | 6.70 ± 0.59b | 7.50 ± 0.44b |
| CRP (mg/L) | 1.56 ± 0.03a | 1.09 ± 0.07b | 1.04 ± 0.08b |
a-bMeans in the same row with different superscripts are significantly different (p ≤ 0.05); values are presented as means ± SEM.
Figure 1Effect of soy isoflavones on total (a) and differential leukocyte count (b) among experimental groups. Bars with different superscripts are significantly different at p < 0.05; values are presented as means ± SEM.
Figure 2Photomicrographs of epiphyseal bone and epiphyseal plate of rat tibia stained with H&E. (a, b, c) Scale bar: 200 μm. (d, e, f) Scale bar: 100 μm. (a, d) OVX/casein group, (b, e) OVX/soy group, and (c, f) sham/casein group. BM: bone marrow; WB: woven bone; CM: zone of cartilage maturation and hypertrophy; CA: zone of cartilage ossification between cartilage and the zone of bone deposition. Arrows represent resorbed bone trabeculae. Head arrows represent well-developed bone trabeculae. Asterisks represent resorbed bone trabeculae.
Figure 3A photomicrograph of a section from tibia bone showing estrogen receptor–α expression. (a) OVX/casein group, (b) OVX/soy group, (c) sham/casein group, and (d) a bar chart showing a comparison of the three groups in the estrogen receptor-α IHC-stained area % (IHC stain, scale bar: 50 μm).